Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT

Home Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT

Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
Read More
Anupam Dalal, MD
Read More
Scott Giacobello, CPA
Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations

Comments

Comments are closed.